Table 3.

Response to azacitidine in individual patients.

Patient	Cytogenetic risk category at diagnosis	Type of response	Time to response (months)	Duration of response (months)	Survival (days) or days alive at LE
1	High	NR	–	–	219
2	Intermediate	NR	–	–	401
3	Intermediate	NR	–	–	13
4	High	NR	–	–	41
5	Intermediate	CR	4	15	908
6	High	HI-P	3	–	–
7	High	CR	2	12	494
8	Intermediate	HI-E, HI-P	3	12	–
9	High	NR	–	–	116
10	Intermediate	PR	1	7	402
11	Intermediate	NR	–	–	120
12	Intermediate	NR	–	–	108
13	Not available	CR	1	–	840 (LE)
14	Intermediate	PR	3	12	509 (LE)
15	Intermediate	NR	–	–	–

High-risk cytogenetics defined as −5, −7, del (5q), abnormal 3q, or complex karyotype with ≥3 cytogenetic abnormalities; intermediate-risk cytogenetics defined as normal and all other karyotypes except t(8;21), t(15;17), and inv(16). CR, complete remission; HI-E, hematologic improvement-erythroid; HI-P, hematologic improvement-platelet; LE, last encounter; NR, no response; PR, partial response.